$1.5 Billion is the total value of Rhenman & Partners Asset Management AB's 92 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PFE | PFIZER INC | $58,400,000 | +35.8% | 1,000,000 | 0.0% | 3.88% | +28.6% | |
| VRTX | VERTEX PHARMACEUTICALS INC | $36,704,000 | +22.6% | 165,000 | 0.0% | 2.44% | +16.2% | |
| MRK | MERCK & CO. INC | $23,142,000 | +2.7% | 300,000 | 0.0% | 1.54% | -2.7% | |
| MRTX | MIRATI THERAPEUTICS INC | $22,235,000 | -16.2% | 150,000 | 0.0% | 1.48% | -20.6% | |
| VEEV | VEEVA SYS INC | $15,601,000 | -9.8% | 60,000 | 0.0% | 1.04% | -14.6% | |
| RCM | R1 RCM INC | $13,860,000 | +14.5% | 550,000 | 0.0% | 0.92% | +8.5% | |
| NKTR | NEKTAR THERAPEUTICS | $13,300,000 | -22.0% | 950,000 | 0.0% | 0.88% | -26.2% | |
| DVAX | DYNAVAX TECHNOLOGIES CORP | $10,665,000 | -26.0% | 750,000 | 0.0% | 0.71% | -29.9% | |
| MGTX | MEIRAGTX HLDGS PLC | $10,454,000 | +76.3% | 450,000 | 0.0% | 0.70% | +67.1% | |
| HCAT | HEALTH CATALYST INC | $9,734,000 | -18.9% | 240,000 | 0.0% | 0.65% | -23.2% | |
| SWAV | SHOCKWAVE MEDICAL INC | $6,108,000 | -12.7% | 34,000 | 0.0% | 0.41% | -17.3% | |
| SGMO | SANGAMO THERAPEUTICS INC | $5,975,000 | -13.3% | 765,000 | 0.0% | 0.40% | -18.0% | |
| ISEE | IVERIC BIO INC | $5,754,000 | +1.2% | 350,000 | 0.0% | 0.38% | -4.0% | |
| AERI | AERIE PHARMACEUTICALS INC | $5,378,000 | -37.1% | 750,000 | 0.0% | 0.36% | -40.3% | |
| PHR | PHREESIA INC | $5,240,000 | -31.2% | 123,465 | 0.0% | 0.35% | -35.0% | |
| SAGE | SAGE THERAPEUTICS INC | $4,974,000 | -2.4% | 115,000 | 0.0% | 0.33% | -7.5% | |
| STXS | STEREOTAXIS INC | $4,976,000 | +15.6% | 800,000 | 0.0% | 0.33% | +9.6% | |
| ALKS | ALKERMES PLC | $4,904,000 | -24.3% | 210,000 | 0.0% | 0.33% | -28.4% | |
| VRAY | VIEWRAY INC | $4,123,000 | -26.2% | 775,000 | 0.0% | 0.27% | -30.1% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $4,074,000 | -26.2% | 1,520,000 | 0.0% | 0.27% | -30.0% | |
| MYOV | MYOVANT SCIENCES LTD | $4,018,000 | -28.4% | 250,000 | 0.0% | 0.27% | -32.2% | |
| PHAT | PHATHOM PHARMACEUTICALS INC | $3,624,000 | -39.4% | 186,210 | 0.0% | 0.24% | -42.6% | |
| GTHX | G1 THERAPEUTICS INC | $3,400,000 | -22.1% | 325,000 | 0.0% | 0.23% | -26.1% | |
| IMCR | IMMUNOCORE HLDGS PLCads | $3,069,000 | -8.0% | 90,000 | 0.0% | 0.20% | -12.8% | |
| ANNX | ANNEXON INC | $2,903,000 | -37.6% | 250,000 | 0.0% | 0.19% | -41.0% | |
| FGEN | FIBROGEN INC | $2,824,000 | +38.2% | 200,000 | 0.0% | 0.19% | +31.5% | |
| OLK | OLINK HLDG ABsponsored ads | $2,619,000 | -22.9% | 140,000 | 0.0% | 0.17% | -26.9% | |
| IONS | IONIS PHARMACEUTICALS INC | $2,291,000 | -8.9% | 75,000 | 0.0% | 0.15% | -14.1% | |
| PIRS | PIERIS PHARMACEUTICALS INC | $1,182,000 | -23.8% | 300,000 | 0.0% | 0.08% | -27.5% | |
| INNV | INNOVAGE HLDG CORP | $741,000 | -25.3% | 150,000 | 0.0% | 0.05% | -30.0% | |
| EPZM | EPIZYME INC | $702,000 | -48.3% | 265,000 | 0.0% | 0.05% | -50.5% | |
| DCPH | DECIPHERA PHARMACEUTICALS INC | $604,000 | -70.4% | 60,000 | 0.0% | 0.04% | -72.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.